FR2377196A1
(fr)
*
|
1977-01-13 |
1978-08-11 |
Lipha |
Composition medicamenteuse a usage oral
|
US4218433A
(en)
*
|
1977-03-03 |
1980-08-19 |
Nippon Kayaku Kabushiki Kaisha |
Constant-rate eluting tablet and method of producing same
|
GB1561204A
(en)
*
|
1977-06-01 |
1980-02-13 |
Ici Ltd |
Sustained release pharmaceutical composition
|
FR2397840B1
(de)
*
|
1977-07-22 |
1981-03-20 |
Cherqui Jean |
|
US4220152A
(en)
*
|
1978-05-08 |
1980-09-02 |
Pfizer Inc. |
Delivery system
|
US4220153A
(en)
*
|
1978-05-08 |
1980-09-02 |
Pfizer Inc. |
Controlled release delivery system
|
US4153677A
(en)
*
|
1978-05-18 |
1979-05-08 |
Sterling Drug Inc. |
Controlled-release composition
|
GB1584130A
(en)
*
|
1978-05-30 |
1981-02-04 |
Wyeth John & Brother Ltd |
Indole derivatives
|
DD146547A5
(de)
*
|
1978-07-15 |
1981-02-18 |
Boehringer Sohn Ingelheim |
Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
|
SE426548B
(sv)
*
|
1978-12-05 |
1983-01-31 |
Haessle Ab |
Fast farmaceutisk beredning innehallande en terapeutiskt effektiv hjertglykosid och en polymer
|
US4173626A
(en)
*
|
1978-12-11 |
1979-11-06 |
Merck & Co., Inc. |
Sustained release indomethacin
|
SE7813246L
(sv)
*
|
1978-12-22 |
1980-06-23 |
Haessle Ab |
Fast farmaceutisk beredning innehallande kroppar med flera ytskikt
|
GB2042888B
(en)
*
|
1979-03-05 |
1983-09-28 |
Teijin Ltd |
Preparation for administration to the mucosa of the oral or nasal cavity
|
FR2454804B1
(fr)
*
|
1979-04-26 |
1986-11-21 |
Sanofi Sa |
Medicament a base de dihydroergotoxine et son procede de preparation
|
FR2470599A1
(fr)
*
|
1979-12-07 |
1981-06-12 |
Panoz Donald |
Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
|
DE3000979A1
(de)
*
|
1980-01-12 |
1981-07-23 |
Dr. Karl Thomae Gmbh, 7950 Biberach |
Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
|
DE3170764D1
(en)
*
|
1980-11-12 |
1985-07-04 |
Ciba Geigy Ag |
Fast disaggregating pharmaceutical tablet
|
EP0052075A1
(de)
*
|
1980-11-12 |
1982-05-19 |
Ciba-Geigy Ag |
Körnige Arzneimittel-Retardform
|
DE3264867D1
(en)
*
|
1981-04-27 |
1985-08-29 |
Haessle Ab |
New pharmaceutical preparation
|
ZA822995B
(en)
*
|
1981-05-21 |
1983-12-28 |
Wyeth John & Brother Ltd |
Slow release pharmaceutical composition
|
DE3126703A1
(de)
*
|
1981-07-07 |
1983-01-27 |
Dr. Karl Thomae Gmbh, 7950 Biberach |
Bromhexin-retardform und verfahren zu ihrer herstellung
|
EP0083372B1
(de)
*
|
1981-07-15 |
1988-05-18 |
Key Pharmaceuticals, Inc. |
Theophyllin mit verlängerter abgabe
|
ZA825384B
(en)
*
|
1981-07-31 |
1983-05-25 |
Tillott J B Ltd |
Orally administrable pharmaceutical compositions
|
JPS5867616A
(ja)
*
|
1981-10-15 |
1983-04-22 |
Tanabe Seiyaku Co Ltd |
腸溶性マイクロカプセル
|
US4370313A
(en)
*
|
1981-10-26 |
1983-01-25 |
Eaton Laboratories, Inc. |
Nitrofurantoin dosage form
|
DK150008C
(da)
*
|
1981-11-20 |
1987-05-25 |
Benzon As Alfred |
Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
|
DE3214667C2
(de)
*
|
1982-04-21 |
1985-07-18 |
Akzo Gmbh, 5600 Wuppertal |
Zusammengesetzter Körper für die Langzeitabgabe von Wirkstoffen
|
US4415547A
(en)
*
|
1982-06-14 |
1983-11-15 |
Sterling Drug Inc. |
Sustained-release pharmaceutical tablet and process for preparation thereof
|
US4508702A
(en)
*
|
1982-06-14 |
1985-04-02 |
Key Pharmaceuticals, Inc. |
Sustained release aspirin
|
WO1984000004A1
(en)
*
|
1982-06-14 |
1984-01-05 |
Key Pharma |
Sustained release aspirin
|
US4557925A
(en)
*
|
1982-07-08 |
1985-12-10 |
Ab Ferrosan |
Membrane-coated sustained-release tablets and method
|
EP0113373B1
(de)
*
|
1982-07-09 |
1991-08-28 |
Key Pharmaceuticals, Inc. |
Dosierungsart zur dauerhaften verabreichung von chinidin
|
US4634587A
(en)
*
|
1982-07-09 |
1987-01-06 |
Key Pharmaceuticals, Inc. |
Sustained release quinidine dosage form
|
US4704284A
(en)
*
|
1982-08-12 |
1987-11-03 |
Pfizer Inc. |
Long-acting matrix tablet formulations
|
US4522625A
(en)
*
|
1982-09-29 |
1985-06-11 |
Alza Corporation |
Drug dispenser comprising wall formed of semipermeable member and enteric member
|
IE55745B1
(en)
*
|
1983-04-06 |
1991-01-02 |
Elan Corp Plc |
Sustained absorption pharmaceutical composition
|
KR880002139B1
(ko)
*
|
1983-04-08 |
1988-10-17 |
베링거 인겔하임 리미티드 |
경구 투여용 정제의 제조방법
|
JPS6051106A
(ja)
*
|
1983-08-31 |
1985-03-22 |
Yamanouchi Pharmaceut Co Ltd |
塩酸アモスラロ−ル持続性製剤
|
US4749575A
(en)
*
|
1983-10-03 |
1988-06-07 |
Bio-Dar Ltd. |
Microencapsulated medicament in sweet matrix
|
US4555399A
(en)
*
|
1983-11-18 |
1985-11-26 |
Key Pharmaceuticals, Inc. |
Aspirin tablet
|
DE3403329A1
(de)
*
|
1984-02-01 |
1985-08-01 |
Horst Dr. 4019 Monheim Zerbe |
Pharmazeutisches produkt in form von pellets mit kontinuierlicher, verzoegerter wirkstoffabgabe
|
DK62184D0
(da)
*
|
1984-02-10 |
1984-02-10 |
Benzon As Alfred |
Diffusionsovertrukket polydepotpraeparat
|
JPS60221078A
(ja)
*
|
1984-04-18 |
1985-11-05 |
Morinaga Milk Ind Co Ltd |
有用微生物粉末の粒状製品およびその製造法
|
GB2159714B
(en)
*
|
1984-06-04 |
1988-05-05 |
Sterwin Ag |
Pharmaceutical composition of sparingly soluble medicament and method for its preparation
|
GB8414221D0
(en)
*
|
1984-06-04 |
1984-07-11 |
Sterwin Ag |
Unit dosage form
|
US4629619A
(en)
*
|
1984-09-05 |
1986-12-16 |
Ab Ferrosan |
Membrane-coated sustained-release tablets and method
|
US4629620A
(en)
*
|
1984-09-05 |
1986-12-16 |
Ab Ferrosan |
Membrane-coated sustained-release tablets and method
|
IE58110B1
(en)
*
|
1984-10-30 |
1993-07-14 |
Elan Corp Plc |
Controlled release powder and process for its preparation
|
US4867984A
(en)
*
|
1984-11-06 |
1989-09-19 |
Nagin K. Patel |
Drug in bead form and process for preparing same
|
IE58246B1
(en)
*
|
1984-12-21 |
1993-08-11 |
Byk Gulden Lomberg Chem Fab |
Theophylline sustained release formulation
|
US5069911A
(en)
*
|
1985-02-05 |
1991-12-03 |
Sandoz Ltd. |
Pharmaceutical 9,10-dihydrogenated ergot alkaloid containing compositions
|
EP0207638B1
(de)
*
|
1985-06-04 |
1990-12-19 |
Teijin Limited |
Arzneizubereitung mit verzögerter Wirkstoffabgabe
|
GB8519310D0
(en)
*
|
1985-07-31 |
1985-09-04 |
Zyma Sa |
Granular active substances
|
GB8521494D0
(en)
*
|
1985-08-29 |
1985-10-02 |
Zyma Sa |
Controlled release tablet
|
SE455836B
(sv)
*
|
1985-10-11 |
1988-08-15 |
Haessle Ab |
Beredning med kontrollerad frisettning innehallande ett salt av metoprolol samt metod for framstellning av denna beredning
|
DE3610878A1
(de)
*
|
1986-04-01 |
1987-10-08 |
Boehringer Ingelheim Kg |
Formlinge aus pellets
|
GB2189698A
(en)
*
|
1986-04-30 |
1987-11-04 |
Haessle Ab |
Coated omeprazole tablets
|
IT1200217B
(it)
*
|
1986-09-30 |
1989-01-05 |
Valducci Roberto |
Membrana per uso farmaceutico ed industriale
|
IT1197316B
(it)
*
|
1986-10-01 |
1988-11-30 |
Proter Spa |
Formulazione galenica ad uso orale di derivati della reina a lento rilascio per impiego terapeutico
|
US4752470A
(en)
*
|
1986-11-24 |
1988-06-21 |
Mehta Atul M |
Controlled release indomethacin
|
IL84599A0
(en)
*
|
1986-12-09 |
1988-04-29 |
Byk Gulden Lomberg Chem Fab |
Pharmaceutical composition containing urapidil and process for the preparation thereof
|
SE460946B
(sv)
*
|
1987-03-16 |
1989-12-11 |
Lejus Medical Ab |
En multipel-unit-dos komposition av kinidinglukonat
|
US5200193A
(en)
*
|
1987-04-22 |
1993-04-06 |
Mcneilab, Inc. |
Pharmaceutical sustained release matrix and process
|
US4786509A
(en)
*
|
1987-05-18 |
1988-11-22 |
Schering Corporation |
Dry sustained release theophylline oral formulation
|
SE8703881D0
(sv)
*
|
1987-10-08 |
1987-10-08 |
Haessle Ab |
New pharmaceutical preparation
|
US4925675A
(en)
*
|
1988-08-19 |
1990-05-15 |
Himedics, Inc. |
Erythromycin microencapsulated granules
|
US4925674A
(en)
*
|
1988-08-25 |
1990-05-15 |
Himedics, Inc. |
Amoxicillin microencapsulated granules
|
US5202128A
(en)
*
|
1989-01-06 |
1993-04-13 |
F. H. Faulding & Co. Limited |
Sustained release pharmaceutical composition
|
US5196203A
(en)
*
|
1989-01-06 |
1993-03-23 |
F. H. Faulding & Co. Limited |
Theophylline dosage form
|
US5122384A
(en)
*
|
1989-05-05 |
1992-06-16 |
Kv Pharmaceutical Company |
Oral once-per-day organic nitrate formulation which does not induce tolerance
|
US5133974A
(en)
*
|
1989-05-05 |
1992-07-28 |
Kv Pharmaceutical Company |
Extended release pharmaceutical formulations
|
US4983401A
(en)
*
|
1989-05-22 |
1991-01-08 |
Kinaform Technology, Inc. |
Sustained release pharmaceutical preparations having pH controlled membrane coatings
|
US4966770A
(en)
*
|
1989-07-26 |
1990-10-30 |
Himedics, Inc. |
Prednisone microencapsulated granules
|
DK0559702T3
(da)
*
|
1990-11-27 |
1995-05-15 |
Byk Gulden Lomberg Chem Fab |
Urapidil-slow-release-præparat
|
US5707652A
(en)
*
|
1990-12-04 |
1998-01-13 |
State Of Oregon |
Methods of treating circadian rhythm phase disorders
|
US6638963B1
(en)
|
1990-12-04 |
2003-10-28 |
Oregon Health And Science University |
Methods for treating circadian rhythm disorders
|
US5162110A
(en)
*
|
1990-12-19 |
1992-11-10 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Binding theophylline to ion exchange resins
|
CA2141582C
(en)
*
|
1992-08-05 |
2003-09-30 |
Angelo Mario Morella |
Pelletised pharmaceutical composition
|
US6440457B1
(en)
*
|
1993-05-27 |
2002-08-27 |
Alza Corporation |
Method of administering antidepressant dosage form
|
US6262115B1
(en)
*
|
1995-05-22 |
2001-07-17 |
Alza Coporation |
Method for the management of incontinence
|
US5912268A
(en)
*
|
1995-05-22 |
1999-06-15 |
Alza Corporation |
Dosage form and method for treating incontinence
|
US6270795B1
(en)
|
1995-11-09 |
2001-08-07 |
Microbiological Research Authority |
Method of making microencapsulated DNA for vaccination and gene therapy
|
ZA977873B
(en)
*
|
1996-09-30 |
1998-04-23 |
Alza Corp |
Dosage form and method for administering drug.
|
AU4801497A
(en)
*
|
1996-09-30 |
1998-04-24 |
Alza Corporation |
Dosage form and method for administering drug
|
US6919373B1
(en)
|
1996-11-12 |
2005-07-19 |
Alza Corporation |
Methods and devices for providing prolonged drug therapy
|
US20020182258A1
(en)
*
|
1997-01-22 |
2002-12-05 |
Zycos Inc., A Delaware Corporation |
Microparticles for delivery of nucleic acid
|
US20040062799A1
(en)
*
|
1997-09-29 |
2004-04-01 |
Ayer Atul D. |
Therapeutic composition and delivery system for administering drug
|
AU4800999A
(en)
*
|
1998-07-28 |
2000-02-21 |
Tanabe Seiyaku Co., Ltd. |
Preparation capable of releasing drug at target site in intestine
|
US6475493B1
(en)
|
1999-09-02 |
2002-11-05 |
Norstrum Pharmaceuticals, Inc. |
Controlled release pellet formulation
|
US20050037086A1
(en)
*
|
1999-11-19 |
2005-02-17 |
Zycos Inc., A Delaware Corporation |
Continuous-flow method for preparing microparticles
|
AU2001268159B2
(en)
*
|
2000-06-02 |
2005-09-15 |
Eisai Inc. |
Delivery systems for bioactive agents
|
US7232924B2
(en)
*
|
2001-06-11 |
2007-06-19 |
Xenoport, Inc. |
Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
|
US8048917B2
(en)
|
2005-04-06 |
2011-11-01 |
Xenoport, Inc. |
Prodrugs of GABA analogs, compositions and uses thereof
|
MXPA03011566A
(es)
*
|
2001-06-11 |
2004-10-28 |
Xenoport Inc |
Formas de dosificacion de profarmacos de analogos de gaba administrados oralmente que tienen toxicidad reducida.
|
WO2002100344A2
(en)
*
|
2001-06-11 |
2002-12-19 |
Xenoport, Inc. |
Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
|
CN101982199A
(zh)
*
|
2001-11-21 |
2011-03-02 |
卫材R&D管理有限公司 |
含有对酸不稳定的生理活性化合物的制剂组合物及其制法
|
US20050163846A1
(en)
*
|
2001-11-21 |
2005-07-28 |
Eisai Co., Ltd. |
Preparation composition containing acid-unstable physiologically active compound, and process for producing same
|
US20050232995A1
(en)
*
|
2002-07-29 |
2005-10-20 |
Yam Nyomi V |
Methods and dosage forms for controlled delivery of paliperidone and risperidone
|
US20050208132A1
(en)
*
|
2002-07-29 |
2005-09-22 |
Gayatri Sathyan |
Methods and dosage forms for reducing side effects of benzisozazole derivatives
|
US20040029959A1
(en)
*
|
2002-08-08 |
2004-02-12 |
John Devane |
Isosorbide mononitrate compositions and methods of their use
|
US7101912B2
(en)
|
2002-12-06 |
2006-09-05 |
Xenoport, Inc. |
Carbidopa prodrugs and derivatives, and compositions and uses thereof
|
US20040162351A1
(en)
*
|
2002-12-11 |
2004-08-19 |
Gallop Mark A. |
Orally administered dosage forms of fused GABA analog prodrugs having reduced toxicity
|
JP2006522146A
(ja)
*
|
2003-03-31 |
2006-09-28 |
ゼノポート,インコーポレイティド |
Gaba類似体のプロドラッグを使用するのぼせの治療または予防
|
EP2354120A1
(de)
|
2003-08-20 |
2011-08-10 |
XenoPort, Inc. |
Synthese von Acyloxyalkylcarbamat-Prodrugs und Zwischenprodukten davon
|
KR101140559B1
(ko)
|
2003-08-20 |
2012-07-05 |
제노포트 인코포레이티드 |
아실옥시알킬 카르바메이트 프로드러그, 합성 및 사용 방법
|
NZ545884A
(en)
*
|
2003-09-11 |
2010-01-29 |
Xenoport Inc |
Treating and/or preventing urinary incontinence using prodrugs of GABA analogs
|
BRPI0414481A
(pt)
*
|
2003-09-17 |
2006-11-14 |
Xenoport Inc |
métodos de tratamento ou de prevenção da sìndrome das pernas inquietas em um paciente e de melhoria do sono em um paciente com sìndrome das pernas inquietas, e, composição farmacêutica
|
US7943585B2
(en)
*
|
2003-12-22 |
2011-05-17 |
Sandoz, Inc. |
Extended release antibiotic composition
|
CN1938026A
(zh)
*
|
2004-03-26 |
2007-03-28 |
卫材R&D管理有限公司 |
控释制剂及其制造方法
|
JP4781352B2
(ja)
*
|
2004-06-04 |
2011-09-28 |
ゼノポート,インコーポレーテッド |
レボドパプロドラッグおよびその組成物ならびにその使用
|
WO2005121070A1
(en)
*
|
2004-06-04 |
2005-12-22 |
Xenoport, Inc. |
Levodopa prodrugs, and compositions and uses thereof
|
US20060128676A1
(en)
*
|
2004-07-13 |
2006-06-15 |
Pharmacofore, Inc. |
Compositions of nicotinic agonists and therapeutic agents and methods for treating or preventing diseases or pain
|
CA2582300A1
(en)
*
|
2004-10-05 |
2006-04-13 |
Altana Pharma Ag |
Oral pharmaceutical preparation comprising a proton pump antagonist and a basic excipient
|
US7494985B2
(en)
*
|
2004-11-03 |
2009-02-24 |
Xenoport, Inc. |
Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use
|
US7566738B2
(en)
*
|
2004-11-03 |
2009-07-28 |
Xenoport, Inc. |
Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use
|
NZ554737A
(en)
*
|
2004-11-04 |
2011-04-29 |
Xenoport Inc |
Gabapentin prodrug sustained release oral dosage forms
|
US7208611B2
(en)
*
|
2005-02-23 |
2007-04-24 |
Xenoport, Inc. |
Platinum-containing compounds exhibiting cytostatic activity, synthesis and methods of use
|
AU2006216646B2
(en)
|
2005-02-23 |
2012-05-31 |
Prexa Pharmaceuticals, Inc. |
Dopamine transporter inhibitors for use in treatment of movement disorders and other cns indications
|
JP4938771B2
(ja)
|
2005-06-20 |
2012-05-23 |
ゼノポート,インコーポレーテッド |
トラネキサム酸のカルバミン酸アシルオキシアルキルプロドラッグ、合成法、および使用
|
US20060293218A1
(en)
*
|
2005-06-22 |
2006-12-28 |
Meythaler Jay M |
Salicylate therapeutic compound and process for controlled delivery thereof
|
WO2007027476A2
(en)
*
|
2005-08-26 |
2007-03-08 |
Xenoport, Inc. |
Treating premature ejaculation using gabapentin and pregabalin prodrugs
|
JPWO2007037259A1
(ja)
*
|
2005-09-29 |
2009-04-09 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
生体内での崩壊性を向上させたパルス製剤
|
RU2429223C2
(ru)
*
|
2005-12-05 |
2011-09-20 |
Ксенопорт, Инк. |
Мезилатное пролекарство леводопы, его композиции и применение
|
NZ569984A
(en)
*
|
2006-01-27 |
2011-06-30 |
Eurand Inc |
Drug delivery systems comprising weakly basic drugs and organic acids
|
BRPI0707324A2
(pt)
*
|
2006-01-27 |
2011-05-03 |
Eurand Inc |
sistemas de fornecimento de fármaco compreendendo agente de bloqueio de serotonina 5-ht3 seletivo fracamente básico e ácidos orgánicos
|
MX2008014794A
(es)
|
2006-05-26 |
2009-04-08 |
Pharmacofore Inc |
Liberacion controlada de opioides fenolicos.
|
US9744137B2
(en)
*
|
2006-08-31 |
2017-08-29 |
Supernus Pharmaceuticals, Inc. |
Topiramate compositions and methods of enhancing its bioavailability
|
WO2008033572A1
(en)
*
|
2006-09-15 |
2008-03-20 |
Xenoport, Inc. |
Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
|
WO2008062320A2
(en)
*
|
2006-10-06 |
2008-05-29 |
Eisai R&D Management Co., Ltd |
Extended release formulations of a proton pump inhibitor
|
US8298576B2
(en)
|
2006-11-17 |
2012-10-30 |
Supernus Pharmaceuticals, Inc. |
Sustained-release formulations of topiramate
|
EA200970487A1
(ru)
*
|
2006-12-08 |
2009-12-30 |
Ксенопорт, Инк. |
Применение пролекарств аналогов гамк для лечения заболеваний
|
JP2011502953A
(ja)
*
|
2006-12-21 |
2011-01-27 |
ゼノポート,インコーポレーテッド |
ジメチル置換されたレボドパジエステルのプロドラッグ、組成物及び使用方法
|
US7829592B2
(en)
*
|
2006-12-21 |
2010-11-09 |
Xenoport, Inc. |
Catechol protected levodopa diester prodrugs, compositions, and methods of use
|
US8133506B2
(en)
*
|
2008-03-12 |
2012-03-13 |
Aptalis Pharmatech, Inc. |
Drug delivery systems comprising weakly basic drugs and organic acids
|
US8399513B2
(en)
*
|
2008-10-20 |
2013-03-19 |
Xenoport, Inc. |
Levodopa prodrug mesylate hydrate
|
CN102186804A
(zh)
*
|
2008-10-20 |
2011-09-14 |
克塞诺波特公司 |
合成左旋多巴酯前药的方法
|
WO2010118362A1
(en)
|
2009-04-09 |
2010-10-14 |
The Regents Of The University Of Colorado, A Body Corporate |
Methods and compositions for inducing physiological hypertrophy
|
US20110003005A1
(en)
*
|
2009-07-06 |
2011-01-06 |
Gopi Venkatesh |
Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
|
US20110060040A1
(en)
*
|
2009-09-04 |
2011-03-10 |
Xenoport, Inc. |
Uses of acyloxyalkyl carbamate prodrugs of tranexamic acid
|
AU2010315892B2
(en)
|
2009-11-09 |
2014-09-18 |
Xenoport, Inc. |
Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
|
CA3018328A1
(en)
|
2014-10-31 |
2016-04-30 |
Purdue Pharma |
Methods and compositions particularly for treatment of attention deficit disorder
|
US10335406B2
(en)
|
2015-10-01 |
2019-07-02 |
Elysium Therapeutics, Inc. |
Opioid compositions resistant to overdose and abuse
|
US9808452B2
(en)
|
2015-10-01 |
2017-11-07 |
Elysium Therapeutics, Inc. |
Polysubunit opioid prodrugs resistant to overdose and abuse
|
AU2018234911B2
(en)
|
2017-03-17 |
2024-04-18 |
Elysium Therapeutics, Inc. |
Polysubunit opioid prodrugs resistant to overdose and abuse
|
US10722473B2
(en)
|
2018-11-19 |
2020-07-28 |
Purdue Pharma L.P. |
Methods and compositions particularly for treatment of attention deficit disorder
|